Akorn, Inc. Announces The FDA Approval Of Akten? Ophthalmic Gel 3.5%
Akorn, Inc. (NASDAQ: AKRX) today announced the FDA approval of NDA 22-221 for Akten? Ophthalmic Gel 3.5%, a topical, ocular anesthetic formulation. The NDA was filed June 29, 2007 following the results from a randomized, placebo controlled, Phase III clinical trial in 209 subjects who met the primary endpoint in all three dosing arms (p
More: continued here
Filed under: Eye Health on October 13th, 2008